Compare Novavax Inc (NVAX) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Quanta Services Inc — how do they compare? Novavax Inc trades at $11.81 (market cap $1.82B), while Quanta Services Inc trades at $688.88 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 56.6× Novavax Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Quanta Services Inc for 62 Days on average.
| NVAX | PWR | |
|---|---|---|
Market Cap | $1.82B | $103.03B |
Volume | 6,198,505 | 977,892 |
Sector | Health | Industrials |
52-Week High | $12.56 | $785.24 |
52-Week Low | $6.22 | $412.21 |
Typical Hold Time | 59 Days | 62 Days |
Enterprise Value | $1.39B | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
PWR trades at $701.07, down 2.57% on the day, but maintains a bullish technical stance with strong support near $690. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $802.08 implying significant upside.
The outlook for PWR is favorable, driven by a record $53B backlog and exposure to AI infrastructure spending. Key risks include execution challenges on large projects and rising debt levels. With 75% of analysts rating it a Buy and strong institutional support, the stock presents a growth opportunity, but investors should monitor cash flow trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
